Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budigalimab and/or ABBV-382 in HIV on stable ART with analytical treatment interruption
NCT06032546Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of budigalimab and ABBV-382 in human immunodeficiency virus infection (HIV) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants with Viral Control Without Antiretroviral Therapy Restart at 24 weeks and Number of Participants with Adverse Events at 112 weeks. Started Oct 2023; status: terminated.
02
Drugs
budigalimabABBV-382
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06032546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06032546.